EAST HANOVER, N.J., Dec. 10, 2017 /PRNewswire/ — Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory…